376 related articles for article (PubMed ID: 24024876)
21. Effects of dopamine and glutamate on synaptic plasticity: a computational modeling approach for drug abuse as comorbidity in mood disorders.
Qi Z; Kikuchi S; Tretter F; Voit EO
Pharmacopsychiatry; 2011 May; 44 Suppl 1():S62-75. PubMed ID: 21544747
[TBL] [Abstract][Full Text] [Related]
22. Gender differences in substance use disorders.
Brady KT; Randall CL
Psychiatr Clin North Am; 1999 Jun; 22(2):241-52. PubMed ID: 10385931
[TBL] [Abstract][Full Text] [Related]
23. Glial and glutamatergic markers in depression, alcoholism, and their comorbidity.
Miguel-Hidalgo JJ; Waltzer R; Whittom AA; Austin MC; Rajkowska G; Stockmeier CA
J Affect Disord; 2010 Dec; 127(1-3):230-40. PubMed ID: 20580095
[TBL] [Abstract][Full Text] [Related]
24. Glutamatergic Transmission: A Matter of Three.
Martínez-Lozada Z; Ortega A
Neural Plast; 2015; 2015():787396. PubMed ID: 26345375
[TBL] [Abstract][Full Text] [Related]
25. The role of glia in late-life depression.
Paradise MB; Naismith SL; Norrie LM; Graeber MB; Hickie IB
Int Psychogeriatr; 2012 Dec; 24(12):1878-90. PubMed ID: 22874475
[TBL] [Abstract][Full Text] [Related]
26. Comorbidity of substance misuse with anxiety-related and depressive disorders: a genetically informative population study of 3 million individuals in Sweden.
Virtanen S; Kuja-Halkola R; Mataix-Cols D; Jayaram-Lindström N; D'Onofrio BM; Larsson H; Rück C; Suvisaari J; Lichtenstein P; Latvala A
Psychol Med; 2020 Jul; 50(10):1706-1715. PubMed ID: 31328718
[TBL] [Abstract][Full Text] [Related]
27. Fetal Alcohol Spectrum Disorders: An Overview from the Glia Perspective.
Wilhelm CJ; Guizzetti M
Front Integr Neurosci; 2015; 9():65. PubMed ID: 26793073
[TBL] [Abstract][Full Text] [Related]
28. Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity.
Enns MW; Swenson JR; McIntyre RS; Swinson RP; Kennedy SH;
Can J Psychiatry; 2001 Jun; 46 Suppl 1():77S-90S. PubMed ID: 11441774
[TBL] [Abstract][Full Text] [Related]
29. Brain Gene Expression Profiling of Individuals With Dual Diagnosis Who Died by Suicide.
Cabrera-Mendoza B; Fresno C; Monroy-Jaramillo N; Fries GR; Walss-Bass C; Glahn DC; Ostrosky-Wegman P; Genis-Mendoza AD; Martínez-Magaña JJ; Romero-Pimentel AL; Díaz-Otañez CE; García-Dolores F; González-Sáenz EE; Mendoza-Morales RC; Flores G; Vázquez-Roque R; Nicolini H
J Dual Diagn; 2020; 16(2):177-190. PubMed ID: 31774731
[No Abstract] [Full Text] [Related]
30. Molecular Neuropathology of Astrocytes and Oligodendrocytes in Alcohol Use Disorders.
Miguel-Hidalgo JJ
Front Mol Neurosci; 2018; 11():78. PubMed ID: 29615864
[TBL] [Abstract][Full Text] [Related]
31. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.
Banasr M; Chowdhury GM; Terwilliger R; Newton SS; Duman RS; Behar KL; Sanacora G
Mol Psychiatry; 2010 May; 15(5):501-11. PubMed ID: 18825147
[TBL] [Abstract][Full Text] [Related]
32. [Depression and addiction comorbidity: towards a common molecular target?].
Arango-Lievano M; Kaplitt MG
Med Sci (Paris); 2015 May; 31(5):546-50. PubMed ID: 26059306
[TBL] [Abstract][Full Text] [Related]
33. Glial degeneration as a model of depression.
Smiałowska M; Szewczyk B; Woźniak M; Wawrzak-Wleciał A; Domin H
Pharmacol Rep; 2013; 65(6):1572-9. PubMed ID: 24553005
[TBL] [Abstract][Full Text] [Related]
34. Major depression and comorbid substance use disorders.
Davis L; Uezato A; Newell JM; Frazier E
Curr Opin Psychiatry; 2008 Jan; 21(1):14-8. PubMed ID: 18281835
[TBL] [Abstract][Full Text] [Related]
35. Comparison of prefrontal cell pathology between depression and alcohol dependence.
Miguel-Hidalgo JJ; Rajkowska G
J Psychiatr Res; 2003; 37(5):411-20. PubMed ID: 12849933
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of depression and substance use and impairment among cocaine users.
Conner KR; Pinquart M; Holbrook AP
Drug Alcohol Depend; 2008 Nov; 98(1-2):13-23. PubMed ID: 18585871
[TBL] [Abstract][Full Text] [Related]
37. Sex differences in depressed substance abusers.
Sinha R; Rounsaville BJ
J Clin Psychiatry; 2002 Jul; 63(7):616-27. PubMed ID: 12143921
[TBL] [Abstract][Full Text] [Related]
38. Potential of Glial Cell Modulators in the Management of Substance Use Disorders.
Jones JD
CNS Drugs; 2020 Jul; 34(7):697-722. PubMed ID: 32246400
[TBL] [Abstract][Full Text] [Related]
39. Glutamate-mediated neuronal-glial transmission.
Verkhratsky A; Kirchhoff F
J Anat; 2007 Jun; 210(6):651-60. PubMed ID: 17504269
[TBL] [Abstract][Full Text] [Related]
40. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy.
Bernstein HG; Steiner J; Bogerts B
Expert Rev Neurother; 2009 Jul; 9(7):1059-71. PubMed ID: 19589054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
